| Ultragenyx Pharmaceuticals Inc. |
69794005050 |
Dojolvi; 500mL; Bottle |
2020-07-01 |
4875.0000 |
Ultragenyx does not have patented marketing information. Any marketing information related to this product is know only to Ultragenyx's Commercial team. Marketing information has potential commercial value and allowing this information to remain non-public and confidential, allows Ultragenyx to obtain a business advantage over its competitors who do not have or know Ultragenyx’s marketing information. Making the marketing information public would not serve the public interest and therefore disclosure is not required. |
None |
1500 |
None |
None |
None |
None |
None |
None |
The estimated prevalence of LC-FAOD is2,000-3,500 LC-FAOD in the US. However this is not the addressable population as many patients with different variants of LC-FAOD may not even know they have the disease. LC-FAOD is a general classification of many genetic mutations that vary in population size and severity. 1,500 patients is the estimation of patients that experience symptoms and seek medical attention due to LC-FAOD.
Dojolvi was developed internally by Ultragenyx. Therefore there was no acquisition price. |
None |